Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Letermovir

Status:

Phase 2

Condition:

Lung Transplant

Intervention Type:

Oral Drug

Funder Type:

Organization | University

Drug Details

Letermovir (PREVYMIS) is a prescription medicine previously approved by the FDA to help to prevent cytomegalovirus (CMV) infection and disease in adults who have received an allogeneic hematopoietic stem cell (bone marrow) transplant and is now being studied in lung transplant recipients (LTRs).

Study Purpose

This is an interventional, open-label, single center, pilot study with historical controls to test the efficacy of letermovir (LET) for the prevention of CMV infection and disease in adult lung transplant recipients (LTRs) with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial